PMID- 36252793
OWN - NLM
STAT- MEDLINE
DCOM- 20230222
LR  - 20230302
IS  - 2666-335X (Electronic)
IS  - 2666-335X (Linking)
VI  - 4
IP  - 1
DP  - 2023 Feb
TI  - Uterine administration of C-X-C motif chemokine ligand 12 increases the pregnancy 
      rates in mice with induced endometriosis.
PG  - 65-73
LID - S2666-335X(22)00065-9 [pii]
LID - 10.1016/j.xfss.2022.10.003 [doi]
AB  - OBJECTIVE: To study the effect of intrauterine injection of C-X-C motif chemokine 
      ligand 12 (CXCL12), also known as a stem cell chemoattractant (stromal 
      cell-derived factor 1), on fertility and endometrial receptivity in mice with 
      endometriosis. DESIGN: Laboratory study. SETTING: Academic Medical Center. 
      ANIMAL(S): Fifty-six mice underwent chemotherapy and bone marrow transplantation. 
      Thirty-six of these mice underwent either surgery to induce endometriosis (n = 
      20) or sham surgery (n = 16). INTERVENTION(S): Injection of CXCL12 as a potential 
      therapeutic agent to improve fertility in endometriosis. MAIN OUTCOME MEASURE(S): 
      Pregnancy rate, bone marrow-derived cell (BMDC) recruitment and endometrial 
      receptivity markers. RESULT(S): The mice with or without endometriosis received a 
      single uterine injection of either CXCL12 or placebo. Uterine injection of CXCL12 
      increased the pregnancy rates in a mouse model of endometriosis. Mice were 
      euthanized after delivery, and implantation markers homeobox A11, alpha-v beta-3 
      integrin, and progesterone receptor were analyzed by immunohistochemistry, 
      whereas green fluorescent protein positive BMDC recruitment was quantified by 
      immunohistochemistry and immunofluorescence. The sham surgery groups without 
      endometriosis had the highest cumulative pregnancy rate (100%) regardless of 
      CXCL12 treatment. The endometriosis group treated with placebo had the lowest 
      pregnancy rate. An increased pregnancy rate was noted in the endometriosis group 
      after treatment with CXCL12. There was also an increase in BMDC recruitment and 
      endometrial expression of progesterone receptor and alpha-v beta-3 integrin in 
      the endometriosis group that received CXCL12 compared with that in the 
      endometriosis group that received placebo. CONCLUSION(S): Uterine injection of 
      CXCL12 increased the pregnancy rates in a mouse model of endometriosis. These 
      results suggest that CXCL12 has a potential role as a therapeutic agent in women 
      with infertility related to endometriosis and potentially other endometrial 
      receptivity defects.
CI  - Copyright (c) 2022 American Society for Reproductive Medicine. Published by 
      Elsevier Inc. All rights reserved.
FAU - Rosa-E-Silva, Ana Carolina Japur de Sa
AU  - Rosa-E-Silva ACJS
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of 
      Medicine, New Haven, Connecticut; Department of Gynecology and 
      Obstetrics-Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao 
      Preto, Brasil.
FAU - Mamillapalli, Ramanaiah
AU  - Mamillapalli R
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of 
      Medicine, New Haven, Connecticut. Electronic address: 
      ramana.mamillapalli@yale.edu.
FAU - Rosa-E-Silva, Julio Cesar
AU  - Rosa-E-Silva JC
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of 
      Medicine, New Haven, Connecticut; Department of Gynecology and 
      Obstetrics-Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao 
      Preto, Brasil.
FAU - Ucar, Abdullah
AU  - Ucar A
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of 
      Medicine, New Haven, Connecticut.
FAU - Schwartz, Joshua
AU  - Schwartz J
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of 
      Medicine, New Haven, Connecticut.
FAU - Taylor, Hugh S
AU  - Taylor HS
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of 
      Medicine, New Haven, Connecticut.
LA  - eng
GR  - U54 HD052668/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20221015
PL  - United States
TA  - F S Sci
JT  - F&S science
JID - 101765857
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Ligands)
RN  - 0 (Integrins)
RN  - 0 (Chemokines)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - Mice
MH  - Animals
MH  - *Endometriosis/drug therapy
MH  - Receptors, Progesterone
MH  - Ligands
MH  - *Infertility, Female
MH  - Integrins
MH  - Chemokines
OTO - NOTNLM
OT  - BMDSC
OT  - CXCL12
OT  - endometriosis
OT  - mice
OT  - pregnancy
EDAT- 2022/10/18 06:00
MHDA- 2023/02/22 06:00
CRDT- 2022/10/17 19:26
PHST- 2022/07/15 00:00 [received]
PHST- 2022/10/06 00:00 [revised]
PHST- 2022/10/11 00:00 [accepted]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2023/02/22 06:00 [medline]
PHST- 2022/10/17 19:26 [entrez]
AID - S2666-335X(22)00065-9 [pii]
AID - 10.1016/j.xfss.2022.10.003 [doi]
PST - ppublish
SO  - F S Sci. 2023 Feb;4(1):65-73. doi: 10.1016/j.xfss.2022.10.003. Epub 2022 Oct 15.